Clinical Trials in Houston

Showing 9481-9500 of 17,885 trials

Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa

NCT04541550

This study is an open-label, dose-escalation study enrolling 15 participants. There are 3 cohorts: 1. Cohort I: 5 subjects each receiving 1 injection of IGN-AMP001 (12.5mg AMP-001 in 3ml Saline) 2. Cohort II: 5 subjects each receiving 1 injection of IGN-AMP001 (25 mg AMP-001 in 3 ml Saline) 3. Cohort III: 5 subjects each receiving 1 injection of IGN-AMP001 (50 mg AMP-001 in 3 ml Saline).

Hidradenitis Suppurativa

IntegoGen, LLCStarted Apr 2021

Houston, Texas, United States

UNKNOWNNA< 1 mile

GARNET™ Filter (GARNET Device) IDE Used in Chronic Hemodialysis Patients With a Bloodstream Infection

NCT04658017

To evaluate the feasibility of performing combined hemodialysis with the GARNET device in chronic hemodialysis patients with a blood stream infection (BSI), and measure clinical performance and safety endpoints.

Bloodstream Infection

Boa Biomedical, Inc.15 participantsStarted Mar 2021

Washington D.C., District of Columbia, United States • Baltimore, Maryland, United States • Bethesda, Maryland, United States +3 more locations

COMPLETEDPhase 2< 1 mile

Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)

NCT00759798

The goal of this clinical research study is to learn more about the characteristics of CLL, including genes and chromosome abnormalities and proteins expressed by the leukemia cells, which may help doctors predict if patients who receive standard treatment (fludarabine, cyclophosphamide, and rituximab) for the first time will experience a complete remission.

Chronic Lymphocytic LeukemiaLeukemia

M.D. Anderson Cancer Center289 participantsStarted Aug 2008

Houston, Texas, United States

Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa

GARNET™ Filter (GARNET Device) IDE Used in Chronic Hemodialysis Patients With a Bloodstream Infection

Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)

Find Trials by Condition in Houston

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

aMAZE Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes

TruGraf® Testing in High-Risk Kidney Transplant Recipients

Verticalization Robotic Exoskeleton DoC

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor

Delphinus SoftVue Prospective Case Collection - ARM 1

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Improving COVID-19 Vaccine Uptake in Nursing Homes

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly